Intranasal (IN ... of providing a constant IN medication dose with acceptable mucosal distribution (Mygind and Vesterhauge). Atomization prepares medication in soluble particles that are optimal ...

The potential of intranasal vaccination is well known against mucosal pathogens, including Mycobacterium tuberculosis, which helps in the designing of new-generation antituberculous vaccines.

For the induction of optimal mucosal immune responses, intranasal vaccination must be administered with an adjuvant. A new study published in Mucosal Immunology shows that α-galactosylceramide ...

a novel inhaled and intranasal mucosal vaccine for COVID-19. This approval enables the commencement of a Phase 1 clinical trial, a highly anticipated step toward addressing unmet needs in COVID-19 ...

This collaboration will leverage Kenox Pharmaceuticals' extensive expertise in nasal and inhaled pharmaceutical ... novel therapies designed to enhance mucosal immunity in individuals with ...